Ivan Goldberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1043578/publications.pdf

Version: 2024-02-01

39	1,297	18	34
papers	citations	h-index	g-index
39	39	39	1751 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension. European Journal of Ophthalmology, 2021, 31, 103-111.	1.3	6
2	Childhood and Early Onset Glaucoma Classification and Genetic Profile in a Large Australasian Disease Registry. Ophthalmology, 2021, 128, 1549-1560.	5.2	20
3	Efficient capture of high-quality real-world data on treatments for glaucoma: the Fight Glaucoma Blindness! Registry. BMJ Open Ophthalmology, 2021, 6, e000903.	1.6	3
4	Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: the glaucoma initial treatment study randomised clinical trial. British Journal of Ophthalmology, 2020, 104, 813-821.	3.9	22
5	Facilitating Patient-Ophthalmologist Dialog: A Call for a Patient-focused Classification of Glaucoma Diagnosis. Journal of Glaucoma, 2020, 29, 329-330.	1.6	O
6	Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. Nature Genetics, 2020, 52, 160-166.	21.4	192
7	Myocilin Gene Gln368Ter Variant Penetrance and Association With Glaucoma in Population-Based and Registry-Based Studies. JAMA Ophthalmology, 2019, 137, 28.	2.5	32
8	Analysis combining correlated glaucoma traits identifies five new risk loci for open-angle glaucoma. Scientific Reports, 2018, 8, 3124.	3.3	33
9	Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma. Nature Genetics, 2018, 50, 1067-1071.	21.4	152
10	Oral Memantine for the Treatment of Glaucoma. Ophthalmology, 2018, 125, 1874-1885.	5.2	97
11	Knocked by the shuttlecock: twelve sightâ€threatening bluntâ€eye injuries in Australian badminton players. Australasian journal of optometry, The, 2017, 100, 365-368.	1.3	14
12	Applications of the water drinking test in glaucoma management. Clinical and Experimental Ophthalmology, 2017, 45, 625-631.	2.6	27
13	Myocilin Predictive Genetic Testing for Primary Open-Angle Glaucoma Leads to Early Identification of At-Risk Individuals. Ophthalmology, 2017, 124, 303-309.	5.2	25
14	Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. Expert Opinion on Drug Safety, 2017, 16, 1071-1078.	2.4	32
15	Incidence of Intraocular Pressure Elevation following Intravitreal Ranibizumab (Lucentis) for Age-related Macular Degeneration. Journal of Current Glaucoma Practice, 2017, 11, 3-7.	0.5	11
16	Activity Limitation in Glaucoma: Objective Assessment by the Cambridge Glaucoma Visual Function Test., 2016, 57, 6158.		14
17	Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma. Expert Opinion on Investigational Drugs, 2016, 25, 1201-1208.	4.1	10
18	Water drinking test: new applications. Clinical and Experimental Ophthalmology, 2016, 44, 87-88.	2.6	9

#	Article	lF	Citations
19	Impact of ageâ€related macular degeneration in patients with glaucoma: understanding the patients' perspective. Clinical and Experimental Ophthalmology, 2016, 44, 377-387.	2.6	10
20	Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors. Expert Opinion on Emerging Drugs, 2016, 21, 117-128.	2.4	7
21	Intra-Ocular Pressure Measurement in a Patient with a Thin, Thick or Abnormal Cornea. Open Ophthalmology Journal, 2016, 10, 35-43.	0.2	11
22	Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial. Trials, 2015, 16, 406.	1.6	17
23	Clinical audit examining the impact of benzalkonium chlorideâ€ree antiâ€glaucoma medications on patients with symptoms of ocular surface disease. Clinical and Experimental Ophthalmology, 2015, 43, 214-220.	2.6	26
24	Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naïve patients vs previously treated patients. Clinical Ophthalmology, 2015, 9, 1605.	1.8	6
25	Cataract and quality of life in patients with glaucoma. Clinical and Experimental Ophthalmology, 2015, 43, 335-341.	2.6	23
26	EX-PRESS glaucoma filtration device: Review of clinical experience and comparison with trabeculectomy. Survey of Ophthalmology, 2015, 60, 327-345.	4.0	36
27	Occurrence of <i>CYP1B1</i> Mutations in Juvenile Open-Angle Glaucoma With Advanced Visual Field Loss. JAMA Ophthalmology, 2015, 133, 826.	2.5	21
28	Crystalline lens malignancy. Clinical and Experimental Ophthalmology, 2014, 42, 705-706.	2.6	1
29	Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. British Journal of Ophthalmology, 2014, 98, 926-931.	3.9	37
30	Twice-Daily Brinzolamide/Brimonidine Fixed Combination versus Brinzolamide or Brimonidine in Open-Angle Glaucoma or Ocular Hypertension. Ophthalmology, 2014, 121, 2348-2355.	5.2	44
31	Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. Nature Genetics, 2014, 46, 1120-1125.	21.4	186
32	Vision loss and partial third nerve palsy following contralateral peribulbar anesthesia. Journal of Cataract and Refractive Surgery, 2013, 39, 132-133.	1.5	9
33	Australian and New Zealand Registry of Advanced Glaucoma: methodology and recruitment. Clinical and Experimental Ophthalmology, 2012, 40, 569-575.	2.6	64
34	A refractive surgery candidate with optic nerve head cupping. Journal of Ophthalmic and Vision Research, 2012, 7, 248-56.	1.0	1
35	Neuroprotective agents in glaucoma therapy: recent developments and future directions. Expert Review of Ophthalmology, 2010, 5, 627-636.	0.6	11
36	Stepping Up Glaucoma Management: When and How?. Open Ophthalmology Journal, 2009, 3, 67-69.	0.2	1

#	Article	IF	CITATIONS
37	Coâ€prescribing of topical and systemic betaâ€blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clinical and Experimental Ophthalmology, 2007, 35, 700-705.	2.6	18
38	Is this neuroprotective drug good for my glaucoma patients? Some key factors in clinical decision-making. Canadian Journal of Ophthalmology, 2007, 42, 418-20.	0.7	2
39	Relationship Between Intraocular Pressure and Preservation of Visual Field in Glaucoma. Survey of Ophthalmology, 2003, 48, S3-S7.	4.0	67